Publications.
Our team’s contributions are regularly recognized by the scientific and medical communities, with our work featured across prestigious conferences and journals.
These publications highlight the breadth and depth of our expertise, from novel applications of machine learning in oncology to translational research advancing clinical care. Each study showcases how our Phenotype Atlas is redefining what is possible in cancer diagnostics and therapeutics.
NIH Pub Med | November 1, 2021
European Association of Urology | September 3, 2024
2024 ASCO Annual Meeting | May 29, 2024
2024 ASCO Genitourinary Cancers Symposium | January 29, 2024
2023 ASCO Annual Meeting | Date TBD
A Novel Artificial Intelligence-powered Tool for Precise Risk Stratification of Prostate Cancer Progression in Patients with Clinical Intermediate Risk
September 3, 2024
Predicting Response of Triple-Negative Breast Cancer to Neoadjuvant Chemotherapy Using a Deep Convolutional Neural Network–Based Artificial Intelligence Tool
March 24, 2023
A Novel Artificial Intelligence-Powered Method for Prediction of Early Recurrence of Prostate Cancer After Prostatectomy and Cancer Drivers
February 6, 2022
Development and Validation of an Artificial Intelligence-Powered Platform for Prostate Cancer Grading and Quantification
November 1, 2021
Example: Top-3 Papers in Journal etc.
PATHOMIQ AI, headquartered in Silicon Valley, USA, was founded by a multidisciplinary team of outstanding biomarker discovery researchers, data scientists, and clinicians with 100+ man-years of experience in their areas of specialty.
CEO & Co-Founder
Chief Medical Officer
Head of Pathology &
Co-Founder
In an era where oncology is evolving at unprecedented speed, our resources aim to keep you informed and inspired.
Stay ahead of the curve with insights that matter.
